Wall Street analyst estimates for Anika Therapeutics, Inc. (ANIK): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies.
Valuation Ratios
| Price / Book | 2.02 |
| EV / EBITDA | 97.19 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $103.4M | $113.4M | $105.6M | $114.6M | $130.5M | $147.8M | $113.8M | $120.8M | $119.9M | $112.8M |
| Cost of Revenue | $24.0M | $27.4M | $31.3M | $28.7M | $61.4M | $64.9M | $40.6M | $38.3M | $43.9M | $49.0M |
| Gross Profit | $79.4M | $86.1M | $74.3M | $85.9M | $69.0M | $82.9M | $73.2M | $82.5M | $76.0M | $63.8M |
| Research & Development | $10.7M | $18.8M | $18.2M | $16.7M | $23.4M | $27.3M | $18.3M | $21.8M | $25.5M | $25.8M |
| Selling, General & Admin | $18.0M | $21.5M | $34.3M | $35.0M | $60.1M | $74.1M | $51.2M | $59.9M | $55.6M | $49.1M |
| Operating Expenses | $28.7M | $40.3M | $52.5M | $51.6M | $97.3M | $80.3M | $69.5M | $81.7M | $81.1M | $74.9M |
| Operating Income | $50.6M | $45.7M | $21.7M | $34.2M | -$28.3M | $2.6M | $3.7M | $844000 | -$5.1M | -$11.1M |
| EBITDA | $54.3M | $50.0M | $27.7M | $40.2M | -$1.0M | -$4.2M | $18.8M | $17.4M | $5.4M | -$3.6M |
| Interest Expense | 0 | 0 | 0 | 0 | $800000 | 0 | 0 | 0 | ||
| Pre-tax Income | $50.9M | $46.2M | $23.2M | $36.1M | -$28.6M | $2.4M | $4.3M | $3.2M | -$2.8M | -$9.3M |
| Income Tax | $18.3M | $14.4M | $4.5M | $8.9M | -$4.6M | -$1.7M | $2.1M | $6.6M | $6.1M | $672000 |
| Net Income | $32.5M | $31.8M | $18.7M | $27.2M | -$24.0M | $4.1M | -$14.9M | -$82.7M | -$56.4M | -$10.9M |
| EPS | $2.22 | $2.18 | $1.30 | $1.93 | $-1.69 | $0.29 | $-1.02 | $-5.64 | $-3.83 | $-0.76 |
| EPS (Diluted) | $2.15 | $2.11 | $1.27 | $1.89 | $-1.69 | $0.28 | $-1.02 | $-5.64 | $-3.83 | $-0.76 |
| Shares Outstanding (Diluted) | $15.1M | $15.1M | $14.7M | $14.4M | $14.2M | $14.6M | $14.6M | $14.7M | $14.7M | $14.3M |
Price
| Price | $20.84 |
| Market Cap | $279M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ANIX · APYX · ARAY · AVR · LNSR · LUCD · MXCT
Explore sector: Healthcare · Medical - Specialties
More sections of ANIK: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks